Published in J Clin Microbiol on February 01, 2001
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother (2006) 1.13
Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 1.13
Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J Clin Microbiol (2005) 1.02
Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi. J Clin Microbiol (2003) 0.97
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother (2005) 0.94
Conidial viability assay for rapid susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 0.93
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species. Antimicrob Agents Chemother (2002) 0.91
Method for measuring postantifungal effect in Aspergillus species. Antimicrob Agents Chemother (2002) 0.90
Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother (2003) 0.89
Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole. Antimicrob Agents Chemother (2003) 0.89
Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. PLoS One (2013) 0.87
The allele-specific probe and primer amplification assay, a new real-time PCR method for fine quantification of single-nucleotide polymorphisms in pooled DNA. Appl Environ Microbiol (2011) 0.86
Utilisation of carbon substrates by orchid and ericoid mycorrhizal fungi from Australian dry sclerophyll forests. Mycorrhiza (2005) 0.86
Repeated-batch production of kojic acid in a cell-retention fermenter using Aspergillus oryzae M3B9. J Ind Microbiol Biotechnol (2005) 0.85
Growth inhibitory response and ultrastructural modification of oral-associated candidal reference strains (ATCC) by Piper betle L. extract. Int J Oral Sci (2014) 0.83
Mycobiota of Underground Habitats: Case Study of Harmanecká Cave in Slovakia. Microb Ecol (2016) 0.82
Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosis. Antimicrob Agents Chemother (2009) 0.80
Effect of culture medium on the disk diffusion method for determining antifungal susceptibilities of dermatophytes. Antimicrob Agents Chemother (2006) 0.79
Utilisation of carbon substrates by multiple genotypes of ericoid mycorrhizal fungal endophytes from eastern Australian Ericaceae. Mycorrhiza (2003) 0.79
Human Neutrophils Are Primed by Chemoattractant Gradients for Blocking the Growth of Aspergillus fumigatus. J Infect Dis (2015) 0.78
Antifungal susceptibility and growth inhibitory response of oral Candida species to Brucea javanica Linn. extract. BMC Complement Altern Med (2013) 0.77
The Pochonia chlamydosporia serine protease gene vcp1 is subject to regulation by carbon, nitrogen and pH: implications for nematode biocontrol. PLoS One (2012) 0.76
Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds. Eur J Clin Microbiol Infect Dis (2009) 0.76
Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2014) 0.76
Time Dependency of Chemodiversity and Biosynthetic Pathways: An LC-MS Metabolomic Study of Marine-Sourced Penicillium. Mar Drugs (2016) 0.75
Morphological Characterization and Quantification of the Mycelial Growth of the Brown-Rot Fungus Postia placenta for Modeling Purposes. PLoS One (2016) 0.75
Exploration of anti-Malassezia potential of Nyctanthes arbor-tristis L. and their application to combat the infection caused by Mala s1 a novel allergen. BMC Complement Altern Med (2016) 0.75
Conidial germination in Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans: influence of growth conditions and antifungal susceptibility profiles. Mem Inst Oswaldo Cruz (2016) 0.75
Heterotrophic Bioleaching of Sulfur, Iron, and Silicon Impurities from Coal by Fusarium oxysporum FE and Exophiala spinifera FM with Growing and Resting Cells. Curr Microbiol (2016) 0.75
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother (1995) 7.74
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. J Clin Microbiol (1986) 3.52
Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol (1992) 3.12
Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother (1983) 3.06
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol (1995) 2.51
The action of miconazole of the growth of Candida albicans. Sabouraudia (1975) 2.32
Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. J Infect Dis (1976) 2.31
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
The new fungal opportunists are coming. Clin Infect Dis (1996) 2.10
Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans. Antimicrob Agents Chemother (1984) 1.88
Factors influencing the susceptibility of Candida albicans to the polyenoic antibiotics nystatin and amphotericin B. J Gen Microbiol (1978) 1.80
Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. J Antimicrob Chemother (1995) 1.77
Standardization of antifungal susceptibility testing. J Antimicrob Chemother (1996) 1.73
Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother (1997) 1.68
Fungistatic activity, uptake and incorporation of 5-fluorocytosine in Candida albicans, as influenced by pyrimidines and purines. I. Reversal experiments. Pathol Microbiol (Basel) (1973) 1.56
Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother (1989) 1.51
Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob Agents Chemother (2000) 1.50
Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B fgainst Fusarium. Antimicrob Agents Chemother (1997) 1.49
Susceptibility testing of fungi and correlation with clinical outcome. J Chemother (1997) 1.38
Standardization of antifungal susceptibility testing and clinical relevance. Med Mycol (1998) 1.33
Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. J Clin Microbiol (1986) 1.30
Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods. Antimicrob Agents Chemother (2000) 1.21
Opportunistic and pathogenic fungi. J Antimicrob Chemother (1991) 1.12
In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother (1995) 1.12
Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. J Gen Microbiol (1975) 1.10
Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans. Mycoses (1996) 0.84
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother (2007) 3.54
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
General primer-mediated PCR for detection of Aspergillus species. J Clin Microbiol (1994) 2.81
Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol (1997) 2.71
Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med (2000) 2.70
Rapid, polymerase chain reaction-based identification assays for Candida species. J Clin Microbiol (1993) 2.70
Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis (1995) 2.69
EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect (2011) 2.65
[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]. Ned Tijdschr Geneeskd (2004) 2.55
Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2001) 2.53
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol (1997) 2.53
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect (2011) 2.38
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol (2007) 2.29
Performance of a nonisotopic DNA probe for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol (1991) 2.21
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species. Clin Infect Dis (1993) 2.13
[Postanginal sepsis caused by Fusobacterium necrophorum: Lemierre syndrome]. Ned Tijdschr Geneeskd (1993) 2.11
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect (2014) 2.06
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy (2013) 2.03
Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol (1999) 2.02
Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol (1995) 1.96
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J Clin Microbiol (1995) 1.89
Aspergillus species identification in the clinical setting. Stud Mycol (2007) 1.81
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Synchronization of Plasmodium falciparum gametocytes using an automated suspension culture system. Parasitology (1986) 1.78
Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol (2000) 1.76
Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun (2001) 1.75
Comparative study of seven commercial yeast identification systems. J Clin Pathol (1999) 1.74
Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol (1994) 1.72
Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol (1996) 1.72
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol (1991) 1.70
Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions. BMJ (1993) 1.65
Increased susceptibility of TNF-alpha lymphotoxin-alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol (1999) 1.64
Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis (2013) 1.61
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother (2000) 1.61
Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis (1996) 1.60
Susceptibility to various antimicrobial agents and tolerance to methicillin of Staphylococcus aureus isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis (1991) 1.57
A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev (1997) 1.57
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2005) 1.55
Characterization of verocytotoxin-producing Escherichia coli O157 isolates from patients with haemolytic uraemic syndrome in Western Europe. Epidemiol Infect (1995) 1.54
Typing of Aspergillus species and Aspergillus fumigatus isolates by interrepeat polymerase chain reaction. J Clin Microbiol (1993) 1.49
Schizophyllum commune as an emerging fungal pathogen: a review and report of two cases. Mycoses (2012) 1.48
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Evaluation of Clearview and Magic Lite tests, polymerase chain reaction, and cell culture for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol (1993) 1.47
Fas-FasL interactions modulate host defense against systemic Candida albicans infection. J Infect Dis (1999) 1.47
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect (2006) 1.45
Patient-to-patient spread of a single strain of Corynebacterium striatum causing infections in a surgical intensive care unit. J Clin Microbiol (1996) 1.44
Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients. J Infect Dis (1994) 1.43
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
Prevention of respiratory failure after hydrochloric acid aspiration by intratracheal surfactant instillation in rats. Anesth Analg (1993) 1.40
[A very serious course of psittacosis in pregnancy]. Ned Tijdschr Geneeskd (1998) 1.39
[An outbreak of psittacosis at a bird-fanciers fair in the Netherlands]. Ned Tijdschr Geneeskd (2008) 1.39
Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis (2000) 1.39
[Invasive aspergillosis: epidemiology, diagnosis and therapy]. Ned Tijdschr Geneeskd (1994) 1.39
Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis. J Clin Pathol (1995) 1.36
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Outbreak of amoxicillin-resistant Haemophilus influenzae type b: variable number of tandem repeats as novel molecular markers. J Clin Microbiol (1997) 1.35
Current management of fungal infections. Drugs (2001) 1.34
Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis (1993) 1.30
An ultrastructural study on the role of Kupffer cells in the process of infection by Plasmodium berghei sporozoites in rats. Parasitology (1983) 1.29
Infections caused by Gemella morbillorum. Lancet (1993) 1.29
Lack of consistent short sequence repeat polymorphisms in genetically homologous colonizing and invasive Candida albicans strains. J Bacteriol (1998) 1.29
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Transformation of sporozoites of Plasmodium berghei into exoerythrocytic forms in the liver of its mammalian host. Cell Tissue Res (1985) 1.27
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother (1998) 1.27
Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol (1999) 1.27
Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection (1997) 1.27
Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med (1998) 1.26
Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol (1998) 1.24
Fatal pulmonary infection caused by the basidiomycete Hormographiella aspergillata. J Clin Microbiol (1997) 1.24
Genotypic characterization of sequential Aspergillus fumigatus isolates from patients with cystic fibrosis. J Clin Microbiol (1996) 1.23
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother (2002) 1.23
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J Clin Microbiol (2005) 1.20
Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother (1995) 1.20
Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther (2000) 1.20
A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection (2009) 1.19
Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med (2002) 1.18
Phylogenetic relationships of five species of Aspergillus and related taxa as deduced by comparison of sequences of small subunit ribosomal RNA. J Med Vet Mycol (1995) 1.18